Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Supernus Pharm (SUPN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,978,636
  • Shares Outstanding, K 51,260
  • Annual Sales, $ 215,000 K
  • Annual Income, $ 91,220 K
  • 36-Month Beta 1.19
  • Price/Sales 9.54
  • Price/Cash Flow 37.63
  • Price/Book 8.06

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.10 +9.82%
on 12/07/17
40.50 -2.10%
on 12/13/17
+2.05 (+5.45%)
since 11/15/17
3-Month
33.30 +19.07%
on 11/07/17
50.04 -20.77%
on 09/18/17
-9.40 (-19.16%)
since 09/15/17
52-Week
23.10 +71.65%
on 01/20/17
50.04 -20.77%
on 09/18/17
+16.00 (+67.65%)
since 12/15/16

Most Recent Stories

More News
Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and Allergan

If you want a Stock Review on CPRX, FLXN, SUPN, or AGN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com shifts focus on Catalyst...

SUPN : 39.65 (+2.72%)
AGN : 171.68 (+0.43%)
CPRX : 4.08 (-0.49%)
FLXN : 25.22 (+3.15%)
Supernus to Present at Three November Healthcare Conferences

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced...

SUPN : 39.65 (+2.72%)
Supernus Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 9:00 AM...

SUPN : 39.65 (+2.72%)
Supernus Announces Third Quarter 2017 Financial Results

-- Third quarter net product sales were $78.1 million, a 40% increase over 2016.

SUPN : 39.65 (+2.72%)
Supernus to Host Third Quarter 2017 Earnings Conference Call

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced...

SUPN : 39.65 (+2.72%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Supernus Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ:SUPN) concerning possible violations of federal securities...

SUPN : 39.65 (+2.72%)
Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Allergan

If you want a Stock Review on CPRX, FLXN, SUPN, or AGN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com revisits the Generic Drugs...

SUPN : 39.65 (+2.72%)
AGN : 171.68 (+0.43%)
CPRX : 4.08 (-0.49%)
FLXN : 25.22 (+3.15%)
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

JNJ : 142.46 (+0.57%)
SUPN : 39.65 (+2.72%)
TEVA : 18.61 (+7.57%)
RHHBY : 30.9000 (+0.88%)
PFE : 37.20 (+2.03%)
GSK : 34.99 (-0.71%)
BMY : 62.41 (+0.45%)
Supernus Drops SPN-810's Lower Dose Test in Phase III Trials

Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.

SUPN : 39.65 (+2.72%)
SHPG : 151.27 (+2.76%)
ACAD : 28.98 (+0.03%)
ADRO : 8.20 (+1.23%)
Supernus Provides Update on SPN-810 Phase III Clinical Trials

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced...

SUPN : 39.65 (+2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

2nd Resistance Point 40.87
1st Resistance Point 39.73
Last Price 39.65
1st Support Level 37.93
2nd Support Level 37.27

See More

52-Week High 50.04
Fibonacci 61.8% 39.75
Last Price 39.65
Fibonacci 50% 36.57
Fibonacci 38.2% 33.39
52-Week Low 23.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.